Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT; Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team .

Clin Infect Dis. 2019 Mar 28. pii: ciy913. doi: 10.1093/cid/ciy913. [Epub ahead of print]

PMID:
31220220
2.

Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.

Castillo-Mancilla JR, Coyle RP, Coleman SS, Morrow M, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL.

AIDS Res Hum Retroviruses. 2019 Jul 30. doi: 10.1089/AID.2019.0024. [Epub ahead of print]

PMID:
31204866
3.

Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.

Brooks KM, Ibrahim ME, Castillo-Mancilla JR, MaWhinney S, Alexander K, Tilden S, Kerr BJ, Ellison L, McHugh C, Bushman LR, Kiser JJ, Hosek S, Huhn GD, Anderson PL.

J Antimicrob Chemother. 2019 Aug 1;74(8):2352-2359. doi: 10.1093/jac/dkz187.

PMID:
31093649
4.

Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.

Brooks KM, Castillo-Mancilla JR, Blum J, Huntley R, MaWhinney S, Alexander K, Kerr BJ, Ellison L, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ.

J Antimicrob Chemother. 2019 Aug 1;74(8):2360-2364. doi: 10.1093/jac/dkz184.

PMID:
31081036
5.

Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV.

Morrow M, Mawhinney S, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Anderson PL, Castillo-Mancilla JR.

J Infect Dis. 2019 Apr 3. pii: jiz144. doi: 10.1093/infdis/jiz144. [Epub ahead of print]

PMID:
30942881
6.

Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest?

Kiser JJ.

Clin Infect Dis. 2019 Mar 28. pii: ciz025. doi: 10.1093/cid/ciz025. [Epub ahead of print] No abstract available.

PMID:
30923805
7.

Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy.

Coyle RP, Schneck CD, Morrow M, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Mawhinney S, Anderson PL, Castillo-Mancilla JR.

AIDS Behav. 2019 Feb 23. doi: 10.1007/s10461-019-02441-8. [Epub ahead of print]

PMID:
30798457
8.

Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy.

Frasca K, Morrow M, Coyle RP, Coleman SS, Ellison L, Bushman LR, Kiser JJ, Zheng JH, Mawhinney S, Anderson PL, Castillo-Mancilla J.

J Antimicrob Chemother. 2019 May 1;74(5):1395-1401. doi: 10.1093/jac/dky559.

PMID:
30668713
9.

Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.

Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Mawhinney S, Anderson PL.

Clin Infect Dis. 2019 Apr 8;68(8):1335-1342. doi: 10.1093/cid/ciy708.

10.

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.

MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ.

J Antimicrob Chemother. 2018 Aug 1;73(8):2112-2119. doi: 10.1093/jac/dky146.

11.

Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.

Seifert SM, Castillo-Mancilla JR, Erlandson K, Morrow M, Gandhi M, Kuncze K, Horng H, Zheng JH, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL.

J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):295-298. doi: 10.1097/QAI.0000000000001596.

12.

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.

Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01710-17. doi: 10.1128/AAC.01710-17. Print 2018 Jan.

13.

Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.

MacBrayne CE, Castillo-Mancilla J, Burton JR Jr, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ.

J Antimicrob Chemother. 2018 Jan 1;73(1):156-159. doi: 10.1093/jac/dkx344.

14.

Cell-line dependent antiviral activity of sofosbuvir against Zika virus.

Mumtaz N, Jimmerson LC, Bushman LR, Kiser JJ, Aron G, Reusken CBEM, Koopmans MPG, van Kampen JJA.

Antiviral Res. 2017 Oct;146:161-163. doi: 10.1016/j.antiviral.2017.09.004. Epub 2017 Sep 11.

15.

Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.

Kiser JJ, Lu D, Rosenkranz SL, Morse GD, DiFrancesco R, Sherman KE, Butt AA; ACTG A5309s study team.

Drugs R D. 2017 Dec;17(4):557-567. doi: 10.1007/s40268-017-0205-9.

16.

Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.

Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM.

JAMA Pediatr. 2017 Nov 1;171(11):1063-1071. doi: 10.1001/jamapediatrics.2017.2007.

17.

Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.

Naggie S, Marks KM, Hughes M, Fierer DS, Macbrayne C, Kim A, Hollabaugh K, Roa J, Symonds B, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Chung R; AIDS Clinical Trials Group (ACTG) A5327 Study Team.

Clin Infect Dis. 2017 Apr 15;64(8):1035-1042. doi: 10.1093/cid/cix025.

18.

Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.

Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ.

World J Gastroenterol. 2017 Mar 7;23(9):1618-1626. doi: 10.3748/wjg.v23.i9.1618.

19.

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.

Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA, The Actg Birth Study Team.

World J Hepatol. 2017 Feb 8;9(4):217-223. doi: 10.4254/wjh.v9.i4.217.

20.

Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.

Jimmerson LC, Clayton CW, MaWhinney S, Meissner EG, Sims Z, Kottilil S, Kiser JJ.

Antiviral Res. 2017 Feb;138:79-85. doi: 10.1016/j.antiviral.2016.12.005. Epub 2016 Dec 9.

PMID:
27956135
21.
22.

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.

Chen X, Seifert SM, Castillo-Mancilla JR, Bushman LR, Zheng JH, Kiser JJ, MaWhinney S, Anderson PL.

PLoS One. 2016 Nov 10;11(11):e0165505. doi: 10.1371/journal.pone.0165505. eCollection 2016.

23.

A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Jimmerson LC, Bushman LR, Ray ML, Anderson PL, Kiser JJ.

Pharm Res. 2017 Jan;34(1):73-83. doi: 10.1007/s11095-016-2040-z. Epub 2016 Sep 15.

24.

Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Clayton C, Austin G, Palmer BE, Zheng JH, Klein B, Kerr BJ, Guida LA, Rower C, Rower JE, Kiser JJ, Bushman LR, MaWhinney S, Anderson PL.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):981-991. Epub 2016 Sep 19.

25.

Role of Transporters in Drug Development.

Arya V, Kiser JJ.

J Clin Pharmacol. 2016 Jul;56 Suppl 7:S7-S10. doi: 10.1002/jcph.784. No abstract available.

PMID:
27385180
26.

Effect of Disease Pathologies on Transporter Expression and Function.

Atilano-Roque A, Roda G, Fogueri U, Kiser JJ, Joy MS.

J Clin Pharmacol. 2016 Jul;56 Suppl 7:S205-21. doi: 10.1002/jcph.768. Review.

PMID:
27385176
27.

Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.

MacBrayne CE, Kiser JJ.

Clin Infect Dis. 2016 Jul 15;63 Suppl 1:S12-23. doi: 10.1093/cid/ciw220. Review. Erratum in: Clin Infect Dis. 2016 Sep 1;63(5):715.

28.

Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.

Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, Kottilil S, Meissner EG, Sims Z, Langness JA, Hodara A, Aquilante CL, Kiser JJ.

J Clin Pharmacol. 2017 Jan;57(1):118-124. doi: 10.1002/jcph.783. Epub 2016 Aug 4.

PMID:
27349952
29.

Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.

Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio DZ.

CPT Pharmacometrics Syst Pharmacol. 2016 Feb;5(2):65-73. doi: 10.1002/psp4.12058. Epub 2016 Feb 2.

30.

Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients.

Fuchs EJ, Kiser JJ, Hendrix CW, Sulkowski M, Radebaugh C, Bushman L, Ray ML, Andrade A.

J Antimicrob Chemother. 2016 Jun;71(6):1597-600. doi: 10.1093/jac/dkw009. Epub 2016 Feb 10.

31.

Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.

Zheng JH, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, Guida LA, Kiser JJ, Bushman LR, Anderson PL.

J Pharm Biomed Anal. 2016 Apr 15;122:16-20. doi: 10.1016/j.jpba.2016.01.038. Epub 2016 Jan 21.

32.

Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.

Wong TC, Lan A, Kiser JJ, Anderson PL, Patel K, Tillman H, Naggie S.

Hepatology. 2016 Sep;64(3):999-1000. doi: 10.1002/hep.28461. Epub 2016 Mar 18. No abstract available.

33.

Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature.

Larson B, Bushman LR, Casciano ML, Oldland AR, Kiser JJ, Kiser TH.

Int J Pharm Compd. 2016 Nov-Dec;20(6):521-525.

PMID:
28339392
34.

Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.

Rower JE, Jimmerson LC, Chen X, Zheng JH, Hodara A, Bushman LR, Anderson PL, Kiser JJ.

Antimicrob Agents Chemother. 2015 Dec;59(12):7671-9. doi: 10.1128/AAC.01693-15. Epub 2015 Sep 28.

35.

Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.

Rower JE, Meissner EG, Jimmerson LC, Osinusi A, Sims Z, Petersen T, Bushman LR, Wolfe P, McHutchison JG, Kottilil S, Kiser JJ.

J Antimicrob Chemother. 2015 Aug;70(8):2322-9. doi: 10.1093/jac/dkv122. Epub 2015 May 13.

36.

Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Wu LS, Rower JE, Burton JR Jr, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ.

Antimicrob Agents Chemother. 2015 Apr;59(4):2179-88. doi: 10.1128/AAC.04618-14. Epub 2015 Feb 2.

37.

Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification.

Jimmerson LC, Ray ML, Bushman LR, Anderson PL, Klein B, Rower JE, Zheng JH, Kiser JJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26;978-979:163-72. doi: 10.1016/j.jchromb.2014.11.032. Epub 2014 Dec 17.

38.

Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.

Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team.

Pediatr Infect Dis J. 2015 Feb;34(2):162-7. doi: 10.1097/INF.0000000000000538.

39.

Intrahepatic antiviral quantification in a patient undergoing orthotopic cadaveric liver transplantation.

Moorehead KJ, Burton JR Jr, Everson GT, Zheng JH, Kerr BJ, Bushman LR, Wang M, Ju C, Nydam T, Kiser JJ.

J Antimicrob Chemother. 2015 Jan;70(1):315-7. doi: 10.1093/jac/dku334. Epub 2014 Sep 11. No abstract available.

40.

Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma.

Chen X, Bushman LR, McAllister KJ, Anderson PL, Kiser JJ.

Biomed Chromatogr. 2014 Dec;28(12):1714-21. doi: 10.1002/bmc.3211. Epub 2014 Apr 24.

PMID:
24760592
41.

Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.

MacBrayne CE, Blum JD, Kiser JJ.

Ann Pharmacother. 2014 Jun;48(6):816-9. doi: 10.1177/1060028014525034. Epub 2014 Mar 10. Review.

PMID:
24615629
42.

Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.

Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 study team.

Antivir Ther. 2014;19(6):613-8. doi: 10.3851/IMP2755. Epub 2014 Feb 17.

43.

Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry.

Jimmerson LC, Zheng JH, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 1;944:18-24. doi: 10.1016/j.jchromb.2013.10.035. Epub 2013 Oct 31.

44.

Priapism induced by boceprevir-CYP3A4 inhibition and α-adrenergic blockade: case report.

Hammond KP, Nielsen C, Linnebur SA, Langness JA, Ray G, Maroni P, Kiser JJ.

Clin Infect Dis. 2014 Jan;58(1):e35-8. doi: 10.1093/cid/cit673. Epub 2013 Oct 2.

45.

Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?

Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team.

Antimicrob Agents Chemother. 2013 Nov;57(11):5619-28. doi: 10.1128/AAC.01096-13. Epub 2013 Sep 3.

46.

History of the meat animal evaluation contest: a pedagogical stimulant.

Kauffman RG, Russell RL, Skaar BR, Kiser JJ, Mandigo RW, Carr TR, Parrett DF.

J Anim Sci. 2013 Sep;91(9):4553-62. doi: 10.2527/jas.2013-6406. Epub 2013 Jul 3.

PMID:
23825347
47.

Drug-drug interactions during antiviral therapy for chronic hepatitis C.

Kiser JJ, Burton JR Jr, Everson GT.

Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):596-606. doi: 10.1038/nrgastro.2013.106. Epub 2013 Jul 2. Review.

48.

The frequency of adjusted renal dosing of tenofovir DF and its effects on patient outcomes.

Langness JA, Hindman JT, Johnson SC, Kiser JJ.

J Pharm Pract. 2013 Aug;26(4):397-400. doi: 10.1177/0897190012465986. Epub 2012 Dec 2.

PMID:
23204147
49.

Direct-acting antiviral agents for hepatitis C virus infection.

Kiser JJ, Flexner C.

Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. Review.

50.

Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers.

Hammond KP, Wolfe P, Burton JR Jr, Predhomme JA, Ellis CM, Ray ML, Bushman LR, Kiser JJ.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):67-73. doi: 10.1097/QAI.0b013e318275da93.

PMID:
23075915

Supplemental Content

Loading ...
Support Center